Inside informationEnglish
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Ose Immunotherapeutics
- Filed
- 27/04/2026, 07:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117960_20260427